Keros Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Keros Therapeutics, Inc. (KROS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are KROS insiders buying or selling?
In the last 12 months, Keros Therapeutics, Inc. insiders reported 6 open-market purchases ($75.8K) and 12 sales ($522.9K) — net selling of $447.2K. Since April 2020, Trabud has recorded 78 Form 4 filings for KROS: 19 buys ($55.7M) and 59 sells ($242.7M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $22.4K by Jean Jacques Bienaime (Director) on Mar 11, 2026. SEC ↗
- The most recent open-market purchase was reported on Aug 19, 2026 (1 months ago).
Key Statistics (April 2020 – Aug 20, 2026)
Total Form 4 filings
78
SEC EDGAR
Insider filers
21
Insider buys (19)
$55.7M
Insider sells (59)
$242.7M
Insider sentiment
Net sellingNet insider flow of $187.0M in net selling since April 2020, and $447.2K in net selling over the last 12 months. 1 insider buy in the last 90 days.
Recent KROS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 20, 2026 | Annita Tanini | Corp. Controller & VP, Finance | Sale | 1.2K | $10.29 | $12.6K | SEC ↗ |
| Aug 20, 2026 | Lorena Raquel Lerner | Chief Scientific Officer | Sale | 3.6K | $10.29 | $36.7K | SEC ↗ |
| Aug 20, 2026 | Esther Cho | Chief Legal Officer | Sale | 4.5K | $10.29 | $46.2K | SEC ↗ |
| Aug 20, 2026 | Charles W. Newton | Director | Sale | 551 | $10.30 | $5.7K | SEC ↗ |
| Aug 19, 2026 | Jean Jacques Bienaime | Director | Purchase | 1.0K | $10.27 | $10.3K | SEC ↗ |
| Jul 17, 2026 | Jean Jacques Bienaime | Director | Purchase | 1.0K | $10.61 | $10.6K | SEC ↗ |
| Jun 17, 2026 | Jean Jacques Bienaime | Director | Purchase | 1.0K | $10.19 | $10.2K | SEC ↗ |
| Jun 15, 2026 | Charles W. Newton | Director | Sale | 550 | $10.04 | $5.5K | SEC ↗ |
| Jun 8, 2026 | Nima Farzan | Director | Sale | 2.6K | $10.73 | $28.2K | SEC ↗ |
| Jun 8, 2026 | Julius Knowles | Director | Sale | 2.6K | $10.73 | $28.2K | SEC ↗ |
| Jun 5, 2026 | Alpna Seth | Director | Sale | 2.6K | $10.72 | $28.1K | SEC ↗ |
| May 19, 2026 | Jean Jacques Bienaime | Director | Purchase | 1.0K | $10.58 | $10.6K | SEC ↗ |
| Apr 17, 2026 | Jean Jacques Bienaime | Director | Purchase | 1.0K | $11.70 | $11.7K | SEC ↗ |
| Mar 11, 2026 | Jean Jacques Bienaime | Director | Purchase | 2.0K | $11.21 | $22.4K | SEC ↗ |
| Feb 20, 2026 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | Sale | 7.0K | $16.17 | $113.4K | SEC ↗ |
| Feb 20, 2026 | Lorena Raquel Lerner | Chief Science Officer | Sale | 3.9K | $16.35 | $63.3K | SEC ↗ |
| Feb 20, 2026 | Esther Cho | SVP, General Counsel | Sale | 4.7K | $16.35 | $77.6K | SEC ↗ |
| Feb 20, 2026 | Keith Regnante | CHIEF FINANCIAL OFFICER | Sale | 4.7K | $16.35 | $77.5K | SEC ↗ |
| Oct 17, 2025 | Kariv Tomer | 10% Owner | Sale | 4.8M | $17.75 | $85.0M | SEC ↗ |
| Oct 15, 2025 | Daniel Schneeberger | 10% Owner | Sale | 5.4M | $17.75 | $95.7M | SEC ↗ |
| Apr 12, 2025 | Daniel Schneeberger | 10% Owner | Purchase | 934.3K | $10.13 | $9.5M | SEC ↗ |
| Jan 24, 2025 | Keith Regnante | CHIEF FINANCIAL OFFICER | Sale | 40.0K | $45.29 | $1.8M | SEC ↗ |
| Aug 15, 2024 | Carl L Gordon | Director | Sale | 250.0K | $44.01 | $11.0M | SEC ↗ |
| Aug 15, 2024 | ORBIMED ADVISORS LLC | Director | Sale | 250.0K | $44.01 | $11.0M | SEC ↗ |
| Jan 8, 2024 | Keith Regnante | Chief Financial Officer | Sale | 40.0K | $45.29 | $1.8M | SEC ↗ |
Showing the 25 most recent of 78 Form 4 filings for Keros Therapeutics, Inc..
Most active KROS insiders
- Julius Knowles19 filings
- Jennifer Lachey16 filings
- Jean Jacques Bienaime6 filings
- Claudia Ordonez5 filings
- Keith Regnante4 filings
Ask anything about KROS insider activity
Use Trabud's AI agent to query Keros Therapeutics, Inc.'s Form 4 history in plain English — "Show me KROS CEO purchases this year" or compare it against any other ticker.
Open the AI agentKROS insider trading FAQ
Are Keros Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Keros Therapeutics, Inc. insiders reported 6 open-market purchases ($75.8K) and 12 sales ($522.9K) — net selling of $447.2K. Since April 2020, Trabud has recorded 78 Form 4 filings for KROS: 19 buys ($55.7M) and 59 sells ($242.7M). Over the full record that is net selling of $187.0M.
How many insiders trade KROS stock?
21 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Keros Therapeutics, Inc.. The most recent filing was accepted on Aug 20, 2026.
Where does Trabud get KROS insider trading data?
All KROS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.